Cargando…
Viral Vectors for the in Vivo Delivery of CRISPR Components: Advances and Challenges
The Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) and its accompanying protein (Cas9) are now the most effective, efficient, and precise genome editing techniques. Two essential components of the CRISPR/Cas9 system are guide RNA (gRNA) and CRISPR-associated (Cas9) proteins. Choos...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133430/ https://www.ncbi.nlm.nih.gov/pubmed/35646852 http://dx.doi.org/10.3389/fbioe.2022.895713 |
_version_ | 1784713565781884928 |
---|---|
author | Asmamaw Mengstie, Misganaw |
author_facet | Asmamaw Mengstie, Misganaw |
author_sort | Asmamaw Mengstie, Misganaw |
collection | PubMed |
description | The Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) and its accompanying protein (Cas9) are now the most effective, efficient, and precise genome editing techniques. Two essential components of the CRISPR/Cas9 system are guide RNA (gRNA) and CRISPR-associated (Cas9) proteins. Choosing and implementing safe and effective delivery systems in the therapeutic application of CRISPR/Cas9 has proven to be a significant problem. For in vivo CRISPR/Cas9 delivery, viral vectors are the natural specialists. Due to their higher delivery effectiveness than other delivery methods, vectors such as adenoviral vectors (AdVs), adeno-associated viruses (AAVs), and lentivirus vectors (LVs) are now commonly employed as delivery methods. This review thoroughly examined recent achievements in using a variety of viral vectors as a means of CRISPR/Cas9 delivery, as well as the benefits and limitations of each viral vector. Future thoughts for overcoming the current restrictions and adapting the technology are also discussed. |
format | Online Article Text |
id | pubmed-9133430 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91334302022-05-27 Viral Vectors for the in Vivo Delivery of CRISPR Components: Advances and Challenges Asmamaw Mengstie, Misganaw Front Bioeng Biotechnol Bioengineering and Biotechnology The Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) and its accompanying protein (Cas9) are now the most effective, efficient, and precise genome editing techniques. Two essential components of the CRISPR/Cas9 system are guide RNA (gRNA) and CRISPR-associated (Cas9) proteins. Choosing and implementing safe and effective delivery systems in the therapeutic application of CRISPR/Cas9 has proven to be a significant problem. For in vivo CRISPR/Cas9 delivery, viral vectors are the natural specialists. Due to their higher delivery effectiveness than other delivery methods, vectors such as adenoviral vectors (AdVs), adeno-associated viruses (AAVs), and lentivirus vectors (LVs) are now commonly employed as delivery methods. This review thoroughly examined recent achievements in using a variety of viral vectors as a means of CRISPR/Cas9 delivery, as well as the benefits and limitations of each viral vector. Future thoughts for overcoming the current restrictions and adapting the technology are also discussed. Frontiers Media S.A. 2022-05-12 /pmc/articles/PMC9133430/ /pubmed/35646852 http://dx.doi.org/10.3389/fbioe.2022.895713 Text en Copyright © 2022 Asmamaw Mengstie. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Bioengineering and Biotechnology Asmamaw Mengstie, Misganaw Viral Vectors for the in Vivo Delivery of CRISPR Components: Advances and Challenges |
title | Viral Vectors for the in Vivo Delivery of CRISPR Components: Advances and Challenges |
title_full | Viral Vectors for the in Vivo Delivery of CRISPR Components: Advances and Challenges |
title_fullStr | Viral Vectors for the in Vivo Delivery of CRISPR Components: Advances and Challenges |
title_full_unstemmed | Viral Vectors for the in Vivo Delivery of CRISPR Components: Advances and Challenges |
title_short | Viral Vectors for the in Vivo Delivery of CRISPR Components: Advances and Challenges |
title_sort | viral vectors for the in vivo delivery of crispr components: advances and challenges |
topic | Bioengineering and Biotechnology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133430/ https://www.ncbi.nlm.nih.gov/pubmed/35646852 http://dx.doi.org/10.3389/fbioe.2022.895713 |
work_keys_str_mv | AT asmamawmengstiemisganaw viralvectorsfortheinvivodeliveryofcrisprcomponentsadvancesandchallenges |